Gilead Sciences (GILD) On a Down Trend: Should I Hold Firm? | Ask A Fool

TL;DR

Gilead Sciences is facing a minor decline in stock value, but it has shown significant growth over the past year. The company's success is largely dependent on its hepatitis C drug, Savaldi, and its upcoming combo pill. Gilead is expected to dominate the market, but long-term concerns arise due to the limited market potential and lack of repeat business. The company's introduction into the cancer drug market presents additional upside potential.

Transcript

hi fools healthcare analyst David Williamson answering viewer questions in the always-popular ask a full series today's question comes from Gul tech who asks Gilead Sciences seems to be on a downtrend is there any specific reasons or should I just hold firm well thanks cultic for the great question and investors often forget that knowing when to se... Read More

Key Insights

• 🍝 Gilead Sciences' stock decline is a minor dip amid significant growth over the past year.
• 🎅 The success of Gilead is heavily dependent on its hepatitis C drugs, particularly Savaldi and an upcoming combo pill.
• 🦺 Market competition, pricing strategies, and potential safety issues could affect Gilead's success.
• 🙃 Gilead's entry into the cancer drug market with idelalisib presents additional upside potential for the company.
• 🖤 Long-term concerns arise due to limited market potential and lack of repeat business for hepatitis C drugs.
• 🏃 Gilead is a well-run company with a mega blockbuster product, making it a promising investment for the short-term.
• ♋ Investors should monitor Gilead's performance in the cancer drug market as a potential catalyst for stock growth.

Questions & Answers

Q: Is there a specific reason for Gilead Sciences' recent downtrend?

The stock decline is minor and can be attributed to short-term fluctuations. Gilead Sciences has shown significant growth over the past year.

Q: What makes Gilead Sciences' hepatitis C drug, Savaldi, unique?

Savaldi, unlike other treatments, does not require interferon and is a once-a-day pill. It has gained FDA approval and is expected to dominate the market.

Q: How does Gilead compare to its main competitor, AbbVie?

AbbVie's regimen for hepatitis C is more complicated and less effective than Gilead's. AbbVie might compete on pricing, potentially impacting Gilead's success.

Q: Is there any long-term concern for Gilead's success in the hepatitis C market?

While Gilead is expected to dominate the market, the limited market potential and lack of repeat business pose long-term concerns for the company.

Summary & Key Takeaways

• Gilead Sciences' stock is experiencing a minor decline, but it has shown substantial growth over the past year.

• The success of Gilead is heavily reliant on its hepatitis C drug, Savaldi, and an upcoming combo pill for genotype 1.

• Gilead is expected to dominate the hepatitis C market, but long-term concerns arise due to the limited market potential and lack of repeat business.

• The company's entry into the cancer drug market with idelalisib provides additional upside potential for its stock.